Ribocure Pharmaceuticals AB is a leading Swedish biotech company that focuses on the development of cutting-edge RNA therapeutics for addressing the significant medical gaps in rare diseases involved in the fields of cardiovascular, renal, and oncology.
The company is dedicated to the discovery and development of groundbreaking drug assets utilizing advanced oligonucleotide technologies. Operating as a subsidiary of Ribo Life Science Co., Ltd., Ribocure combines the advantages of a vertically integrated oligonucleotide research platform and the profound expertise in translational and clinical operations. In 2022, we successfully progressed three projects to the clinical stage, achieving an impressive average time frame of 20-24 months from concept to implementation.
